Rocket Lab's iQPS Launch Deal Reinforces Backlog but Underlines Persistent Execution Risks

What happened

Rocket Lab announced a multi-launch agreement with iQPS for three new Electron launches, extending an existing partnership and adding to its backlog. This news aligns with the company's strategy to leverage its launch services segment, which contributed $475.6 million to the $1.85 billion backlog at the end of 2025. However, the DeepValue report critically notes that only about 37% of this backlog is expected to convert to revenue within 12 months, down from 57%, signaling weaker near-term visibility. Moreover, Rocket Lab faces heightened execution risk from the Neutron program, which experienced a tank qualification failure in January 2026 and has a first launch target reset to Q4 2026. While this deal supports Electron utilization, it does not address the fundamental challenges of slow backlog conversion and ongoing Neutron development uncertainties.

Implication

The iQPS deal provides incremental revenue and reinforces Rocket Lab's position in the small launch market, supporting Electron cadence and operational stability. However, investors must remain cautious as the backlog conversion rate has deteriorated, with only 37% expected within 12 months, undermining the 'visibility' narrative. Critical execution risks persist, particularly with Neutron, where any further schedule slips could increase cash burn and dilution pressure. Key monitoring points include Q1 2026 revenue meeting the $185M-$200M guidance and Neutron milestone progress, such as cryo-proof testing by August 2026. Overall, this news is marginal and does not warrant a shift from the WAIT rating, emphasizing the need for tangible progress on financial and engineering fronts.

Thesis delta

The iQPS launch agreement is a positive but incremental data point that does not materially alter the investment thesis. Core risks—Neutron development schedule uncertainty and sluggish backlog conversion—remain intact, with no evidence of improvement in these areas. Investors should continue to await validation from upcoming revenue reports and Neutron milestones before reconsidering the position.